Related Experiment Video
Updated: Jul 18, 2026
11:32
Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
Published on: January 3, 2025
Catecholamines, infection, and death in acute ischemic stroke
Angel Chamorro1, Sergio Amaro, Martha Vargas
1Stroke Unit, Hospital Clínic and Institut d' Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain. achamorro@ub.edu
Journal of the Neurological Sciences
|November 30, 2006
Summary
Acute ischemic stroke may trigger fatal infections by activating the sympathetic nervous system, increasing infection risk and mortality. This brain-induced immunodepression syndrome impacts patient outcomes.
Area of Science:
- Neuroscience
- Immunology
- Cardiovascular Medicine
Background:
- Experimental studies suggest acute ischemia can lead to fatal infections via brain-induced immunodepression.
- Mechanisms and neurological consequences of infections complicating acute ischemic stroke are understudied at the clinical level.
Purpose of the Study:
- To investigate the incidence of infection and death after non-septic stroke.
- To analyze longitudinal changes in cytokines, leukocytes, normetanephrine (NMN), and metanephrine (MN) in stroke patients.
Main Methods:
- Prospective study of 75 consecutive patients with non-septic stroke.
- Multivariate analysis correlating infection and mortality with biomarkers including cytokines (IL-10, IL-6), leukocytes, NMN, and MN.
- Assessment of neurological impairment using the National Institutes of Health Stroke Scale (NIHSS).
Main Results:
- Infection (17%) was associated with higher metanephrine (MN) levels, neurological impairment (NIHSS), monocyte count, and increased interleukin (IL)-10.
- Mortality at 3 months (21%) was linked to elevated normetanephrine (NMN) levels, NIHSS score, and higher IL-6.
- These associations were independent of circulating cytokines and leukocytes.
Conclusions:
- Acute ischemic stroke activates the sympathetic adrenomedullar pathway, increasing infection susceptibility and mortality risk.
- This activation appears to be a primary driver, separate from inflammatory cytokine and leukocyte effects.
- Findings highlight the critical role of the sympathetic nervous system in post-stroke complications.
Related Concept Videos
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...